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Introduction: The treatment of esophageal cancer remains clinically challenging because of the overall poor
prognosis associated with the disease. The mortality rate associated with surgical treatment is high, and the
majority of diagnosed patients are old. As such, surgery is not possible in many cases, even when the cancer has
progressed to a resectable state.
Case presentation: We present the case of an 82-year-old Korean man who presented to our institution with
intermittent odynophagia. Esophageal cancer with submucosal invasion and metastasis to three regional lymph
nodes was diagnosed. After neoadjuvant chemoradiotherapy, his regional lymph nodes disappeared. Because of his
poor pulmonary function, surgical treatment could not be performed. Endoscopic submucosal dissection was
carried out instead, and endoscopic triamcinolone injections were performed serially. Neither recurrence nor
abnormal symptoms such as dysphagia or regurgitation have developed for 36 months.
Conclusions: The literature suggests that endoscopic submucosal dissection after chemoradiotherapy is a viable
treatment modality in patients with esophageal cancer with a high surgical treatment risk.
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Esophageal cancer is a highly lethal malignancy with a
5-year survival rate of approximately 15% [1]. Thus, the
management of patients with esophageal cancer is chal-
lenging and requires a multimodal approach. Suboptimal
results have been reported for post-operative adjuvant
chemotherapy [2], radiotherapy [3] and concurrent che-
moradiotherapy [4]; thus, interest in neoadjuvant treat-
ment has recently increased. In particular, Sjoquist et al.
reported that, among patients with resectable esophageal
cancer, those who received neoadjuvant chemoradio-
therapy showed a significant survival benefit compared
to patients who received surgical treatment alone [5].
However, the incidence of esophageal cancer and squa-
mous cell carcinoma is known to increase with age. The* Correspondence: storm5333@naver.com
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man life [6]. Thus, even if resection is possible, surgical
treatment cannot be performed in some patients because
of their general condition or accompanying comorbidi-
ties at the time of diagnosis. In this report, we describe
the case of a patient with esophageal cancer who could
not undergo surgical treatment because he also had
chronic obstructive pulmonary disease (COPD). We suc-
cessfully treated the patient with endoscopic submucosal
dissection (ESD) after concurrent chemoradiotherapy.
Our description of the case is accompanied by a discus-
sion of relevant literature.
Case presentation
An 82-year-old Korean man was admitted to our hos-
pital with a chief complaint of intermittent odynophagia
of approximately 3 months’ duration. The patient did
not have a history of alcohol intake. He was a currentis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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daily for 60 years). He had been taking medication and
using an inhaler for approximately 20 years to treat his
COPD. A pulmonary function test (performed approxi-
mately 2 months prior to his presentation) revealed poor
respiratory function with a forced expiratory volume in 1
second of approximately 45%.
An endoscopic examination showed a broad, ulcerative
lesion at 33cm to 38cm from the incisor that spanned
more than three-fourths of the esophageal lumen circum-
ference (Figures 1A and 1B). The biopsy findings indi-
cated moderately differentiated squamous cell carcinoma.
Endoscopic ultrasonography (EUS) revealed a blurring
and thickening of the third layer (submucosal layer).
However, the fourth layer (proper muscle layer) was
spared. In addition, we observed three malignant lymph
nodes >10mm that were round in shape, had smooth
features and exhibited hypoechogenicity. They were lo-
cated 27cm, 28cm and 42cm from the incisor (Figures 2A,
2B, 2C and 2D). However, we did not find any metastases
on a computed tomography (CT) scan or a positron emis-
sion tomography (PET)-CT scan.
The patient was clinically diagnosed with T1b N2 M0
G2, stage IIIA cancer (according to the American JointFigure 1 Endoscopic examination. Esophageal cancer was observed at the
luminal circumference. (A) White light endoscopy. (B) Chemoendoscopy with
approximately half of the circumference of the esophageal lumen. (C) WhiteCommittee on Cancer (AJCC) staging system [7]) and
treated with concurrent chemoradiotherapy. His chemo-
therapy was 5-fluorouracil plus cisplatin, and his radio-
therapy of 50 Gy was delivered in 25 fractions. In a
follow-up endoscopic examination performed after 5
weeks of chemoradiotherapy, we found that the lesion
had decreased in size to approximately one-half the cir-
cumference of the esophageal lumen. The ulceration also
demonstrated a pattern of improvement upon macro-
scopic observation (Figures 1C and 1D). In addition, the
previously observed malignant lymph nodes were not
seen on follow-up EUS, CT and PET-CT scans. After
chemoradiotherapy, the patient showed a sufficient re-
sponse to be clinically down-staged to T1a/T1b N0 M0
G2, stage IA (according to the AJCC staging system [7]).
Though additional surgical treatment was considered
with the goal of a complete cure, we acquired informed
consent for ESD instead after explaining to the patient
and his guardian the high post-operative risk posed by
his class IV condition (American Society of Anesthe-
siologists classification), which was due to his poor pul-
monary function (Figures 3A, 3B and 3C). A specimen
measuring approximately 5×4.8cm in size was acquired
through an en bloc resection (Figure 4A). Using themiddle to distal esophagus. It spanned more than three-fourths of the
iodine staining. After chemoradiotherapy, the lesion size decreased to
light endoscopy. (D) Chemoendoscopy with iodine staining.
Figure 2 Endoscopic ultrasonography findings. (A) Blurring and thickening of the submucosal layer were observed, but the proper muscle
layer was spared. Three enlarged regional lymph nodes (>10mm) were observed at 42cm (B), 28cm (C) and 27cm (D) from the incisor.
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differentiated squamous cell carcinoma with focal ob-
servation of submucosal invasion (sm1, shallower one-
third of the submucosa) (Figure 4B).
After ESD, the patient developed an iatrogenic ulcer
covering nearly the total circumference of the esopha-
geal lumen. We therefore predicted a high possibility of
secondary luminal stenotic change in the future. Conse-
quently, we administered endoscopic triamcinolone in-
jections (ETIs) on the third, seventh and tenth days
after ESD. Follow-up endoscopic examinations were
performed at 1 week and at 1, 3 and 6 months after
ETI (Figure 5A, 5B, 5C and 5D). They showed neither
luminal stenosis nor local recurrence. In addition, eso-
phagography and esophageal manometry tests performed
3 months after ETI did not yield findings of particular
interest.
The patient has been followed on an outpatient basis
and has not displayed abnormal symptoms such as dys-
phagia or regurgitation. Currently, neither local nor dis-
tant recurrences of esophageal cancer have been observed
after 36 months.
The study protocol was approved by Daegu Fatima
Hospital Ethics Committee. The patient gave us written
informed consent before the procedure.Discussion
As is the case with the majority of gastrointestinal tract
malignancies, esophageal cancer has a potentially cura-
tive therapy consisting of surgical treatment (esophagec-
tomy with therapeutic lymphadenectomy). However,
with recent reports of survival benefits [8] and complete
resection rate increases in patients receiving neoadjuvant
chemoradiotherapy [9], that approach has received at-
tention as a standard treatment for locally advanced
esophageal cancer [10]. Our patient had stage IIIA dis-
ease at the time of initial diagnosis, but restaging after
neoadjuvant chemoradiotherapy showed a significant
down-staging effect to stage IA disease.
It is well known that the surgical risk of esophagec-
tomy varies by clinical characteristics such as age and
comorbidities. Finlayson et al. reported that the 30-day
mortality of esophagectomy was 10.7% among patients
in their 60s, but that it increased to 20% among patients
in their 80s [11]. Moreover, it is well known that the
presence and severity of comorbidities affect disease
prognosis as well as surgical outcome. Our patient was
82 years old and exhibited poor pulmonary function.
Therefore, we could not perform surgical treatment, des-
pite the fact that his esophageal cancer remained in a re-
sectable state, and we performed ESD instead.
Figure 3 Endoscopic submucosal dissection. (A) Pre-cutting was performed along the outer border of the lesion. (B) Submucosal dissection
was performed. (C) A large iatrogenic ulcer was observed after the procedure.
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patients with esophageal cancer with submucosal inva-
sion, because there is a substantial risk of regional lymph
node metastasis. Ancona et al. reported confirmation of
lymph node metastasis in approximately 28% of esopha-
geal cancers with submucosal layer invasion [12]. In our
patient, EUS performed during diagnosis showed inva-
sion of the submucosal layer and three regional meta-
static nodes. However, EUS performed after neoadjuvant
chemoradiotherapy showed an absence of these regionalFigure 4 Pathologic findings. (A) Macroscopic finding of a specimen app
carcinoma with focal submucosal invasion.lymph nodes, and ESD was planned only then. Clearly,
ESD would not have been planned as a follow-up treat-
ment if, in the initial diagnosis, there were EUS or CT
findings that the lesion had invaded the muscularis pro-
pria or adventitia or any adjacent structures. Furthermore,
we could not directly confirm T stage improvement by
EUS prior to ESD, because radiation-induced inflamma-
tion of the esophageal wall and residual disease cannot
be differentiated easily on EUS scans after neoadjuvant
chemoradiotherapy [13]. However, at the time of initialroximately 5cm in size after en bloc resection. (B) Squamous cell
Figure 5 Endoscopic findings after endoscopic triamcinolone injection. (A) 1 week post-injection. (B) 1 month post-injection. (C) 3 months
post-injection. (D) 6 months post-injection.
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lesion. In addition, as regional lymph nodes showed im-
provement following neoadjuvant chemoradiotherapy,
we indirectly predicted that the T staging of the lesion
would not progress beyond T1b. We therefore tho-
roughly explained the process to the patient and his
guardians and acquired informed consent to proceed
with ESD.
After neoadjuvant chemoradiotherapy, the lesion area
decreased significantly. However, as we performed ESD
with a sufficient lateral safety margin, an iatrogenic ulcer
that occupied the majority of the short axis of the esopha-
geal lumen unavoidably developed post-operatively. We
therefore performed ETI to prevent a secondary luminal
stricture. The ETI was performed following a protocol
described by Hashimoto et al. [14]. In accordance with
that protocol, triamcinolone acetonide (10mg/ml) was
placed in a 1-ml syringe. Then, a 25-gauge, 4mm needle
(FINEMEDIX, Daegu, South Korea) was used to inject
the triamcinolone in increments of 0.2ml (2mg) at 1cm
intervals along the long axis and short axis of the ulcer
base [14]. No luminal stricture was observed in a follow-
up endoscopic examination performed after triamcinolone
injection.
The patient remained in a disease-free state without
local or distant recurrence 36 months after ESD. This isconsidered to be due to the fact that the cancer differ-
entiation was not “poor” and the regional lymph node
metastases resolved as a result of neoadjuvant chemo-
radiotherapy. The primary cancer site was also success-
fully treated to R0 resection through ESD and now shows
a good prognosis.
Conclusions
On the basis of our experience in this case, we think that
ESD treatment can be considered in patients with re-
sectable esophageal cancer if surgery poses a high risk
because of comorbidities or the age of the patient and if
there is a good response to neoadjuvant chemoradiother-
apy. Furthermore, with respect to the large iatrogenic
ulcer that occurred after ESD in our patient, we found
that triamcinolone injection via endoscopy was effective in
preventing luminal stricture.
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